New Retina Radio by Eyetube Eyetube
-
- Science
-
New Retina Radio is a place to hear stories about retina that are told nowhere else.
-
The State of Biosimilars: Integration of Biosimilars into a Retina Practice
Biosimilars in retina are here. How are practices integrating them into their clinics? And how do they navigate issues around payer policy, protocol changes, and ensuring continuity of care?
Moderator John Kitchens, MD, sits down with retina specialist Dave Brown, MD, and Kristin Yockus, the VP of Process Integrations at Retina Consultants of America, to answer these questions, and to preview how the coming increase in biosimilar options might play out in a real-world landscape. -
New Retina Radio Journal Club with VBS: Comparison of Antiseptics Use for IVT
How do endophthalmitis rates after intravitreal injection differ after using povidone-iodine compared with chlorhexidine? Moderator Sruthi Arepalli, MD, hears from panelists Vaidehi Dedania, MD, and Rebecca Soares, MD, MPH, about a recent peer-reviewed retrospective cohort study on this topic. After the break, the trio discuss how to manage patients who do not tolerate antiseptics, the benefits of visualizing antiseptics on the conjunctiva, and the specific practice patterns that work best in their clinics.
-
Successful Management of Vitreous Opacities
Performing surgery for symptomatic vitreous opacities (SVO) was once verboten in retina medicine, but the field has seen a sea-change in mindset over the past decade. In this podcast, moderator John Kitchens, MD, is joined by Edwin H. Ryan, MD; Christina Y. Weng, MD, MBA; and Alison Bozung, OD, to explore why surgery for SVO has become more palatable and how this evolution in mindset is impacting patients' quality of life.
-
New Retina Radio Journal Club with VBS: Visual Outcomes Following Surgical RRD Repair Relative to Foveal Status and Time of Surgery
Do the status of the fovea and/or the timing of surgery affect visual outcomes following RRD repair? Join New Retina Radio Journal Club host Lediana Goduni, MD, as she and panelists Matt Starr, MD, and Joshua Uhr, MD, dissect the findings of a recent paper exploring this question. After the break, the trio discusses tactics for overcoming challenges to real-world conditions when patients present at times when immediate surgery is not an option.
-
Treating Geographic Atrophy (GA) In Your Practice
Sponsored by Apellis Pharmaceuticals. Scott Walter, MD, and Esther Kim, MD, join John W. Kitchens, MD, to discuss how they treat GA in their practices. Listen to gain expert insights as Drs. Kim, Walter, and Kitchens each share their experiences with this treatment. They also share best practices for dosing based on trial data.
-
Diagnosing Geographic Atrophy (GA) and Identifying Eligible Patients For Therapy
Sponsored by Apellis Pharmaceuticals. John W. Kitchens, MD, invites Scott Walter, MD, and Esther Kim, MD, to discuss best practices for identifying appropriate patients with GA for treatment. Gain perspectives on patient selection, patient education, and safety considerations.
Customer Reviews
Depressing
I have yet to hear information regarding retinitis pigmentosa! 😩 have advanced arRP. Need stem cell and crisper. Rare gene (RP59) small enough for gene therapy but I’m too advanced for gene therapy. Traveled all over the world, including Japan. Will do ANYTHING to be in a clinical trial. Please help. Only 37.
June 22, 2020 podcast!!!
The one about $LCTX is very interesting!!
NRR rocks!
Awesome podcast! Very relevant for retina surgeons. John Kitchens is a master interviewer and moderator.